摘要
药品的风险,是指药品在有效地控制和治疗疾病的同时,某些患者可能经历的不良事件,甚至是危及生命、致伤致残的严重不良事件。服用任何药品都具有一定的风险.由于药品上市前的临床研究病例少、目的单纯、研究时间短.导致一些药品的不良反应在上市前不易发现.故药品上市后有关风险的不可知因素依然存在。
出处
《中国现代医药杂志》
2009年第12期122-123,共2页
Modern Medicine Journal of China
参考文献3
-
1Peter Aquino,无.药物警戒概述[J].中国药物警戒,2009,6(1):60-62. 被引量:4
-
2杜为民,张京华.药物警戒的重要性与药物警戒论[M].上海:上海科技教育出版社.2004:11-16.
-
3迟丹怡,王大猷,李虹影,李中东,时颖华,王宏图,钟明康.药师在药物警戒中的作用[J].中国医院药学杂志,2005,25(1):75-76. 被引量:25
二级参考文献12
-
1[1]Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events[J]. JAMA. 1995,274(1):35.
-
2[2]Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit[J]. JAMA. 1999 ,282(3):267.
-
3[3]Bates DW, Leape LL, Culen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors[J]. JAMA, 1998,280(15): 1311.
-
4[4]Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Phar Ther,1981,30(2):239~45.
-
5[5]Report of the Quality Interagency Coordination Task Force (QUIC). Doing what counts for patient safety: Federal actions to reduce medical errors and their impact[J]. 2002; February: 37.
-
6[6]Classen DC, Pestotnik SL, Evars RS, et al. Adverse drug events in hospitalized patients[J]. JAMA, 1997, 277(17):301.
-
7[7]Miyagawa CI, Rivera JO. Effect of pharmacist intervention on drug therapy at a surgical intensive care unit[J]. Am J Hosp Pharm, 1986,43(5):3008.
-
8US Food and Drug Administration(FDA).Milestones in US Food and Drug Law History. http://www.fda.gov/opacom/backgrounders/miles.html . 2008
-
9Johnson.Benefit Risk Management.Primer For Drug Safety Compliance[]..2005
-
10Man R,Andrews E B.Pharmacovigilance[]..2002
共引文献27
-
1王越,崔佳,余伯阳,肖诗鹰.我国药物警戒文献计量学分析[J].中国药物警戒,2007,4(2):87-89. 被引量:3
-
2邱季,范鲁雁.临床药师在医疗质量检查中的作用和地位[J].中国医院药学杂志,2007,27(5):683-685. 被引量:63
-
3章六滨,赵启春,孙宏杰.三级医院如何发挥医药护人员作用,提高ADR报告数量与质量[J].中国医药指南(学术版),2008,6(11):168-172. 被引量:1
-
4梁月晴,王珩,王丽,钱文,朱成.中药注射剂临床合理使用对策[J].中国中医药信息杂志,2008,15(11):107-108. 被引量:11
-
5张峻,傅文,王继堃.医疗机构在药物警戒中的地位与作用[J].中国药房,2009,20(2):81-83. 被引量:18
-
6傅文,杜娟,王继堃,韩宏昇,王军,张峻,欧阳楠,邢亚伟,刘巍.试论我国医疗机构在药物警戒中的作用[J].中国药物警戒,2009,6(4):193-197. 被引量:14
-
7周淑红.药师在抗生素合理应用中的作用[J].中国误诊学杂志,2009,9(9):2258-2259.
-
8任建业,王华,靳毅华,李建富.我院开展药物警戒的探索[J].中国药房,2009,20(26):2001-2003.
-
9郭红,杜淑娴,闫素英,张丽.药物警戒工作从细节抓起[J].实用药物与临床,2010,13(1):53-54. 被引量:1
-
10赵阿娜,刘磊.浅谈医院药品风险管理[J].中国药事,2010,24(5):419-422. 被引量:18
同被引文献11
-
1王大猷.药物警戒刍议[J].中国药物警戒,2004,1(1):20-24. 被引量:25
-
2Guidance for Industry,Pharmacogivilance of Veterinary Medicinal Products:Management of Periodic Summary Update Reports(PSUs). VICH GL29 .
-
3Guidance for Industry,Postmarketing Safety Reporting forHuman Drug and Biological,Products Including Vaccines. .
-
4Talbot,J.C.C,Nilsson,B.S.Pharmacovigilance in the pharma-ceutical industry. Br.J.Clin.Pharmacol . 1998
-
5Peachey,J.From Pharmacovigilance to Pharmacoperformance. Drug Safety . 2002
-
6Regulation(EC)No726/2004of the European Parliament and of the Council of31March2004laying down the Community procedures for the authorization and supervision of medical prod-ucts for human and veterinary use and establishing a European Medicines Agency. Official Journal of the European Union . 2004
-
7A.Helali.Essential Drugs and Other Pharmaceuticals. NCPM of Algeria Newsletter: Pharmacovigilance and Vigilance . 2005
-
8The European Parliament and the Council of the EuropeanUnion.Directive 2001/83/EC of the European parliamentand of the council of 6 November 2001 on the communitycode relating to medicinal products for human use. Official Journal L311 . 2004
-
9WHO.The Importance of Pharmacovigilance Safety monitor-ing of medicinal products. . 2002
-
10Peter Aquino,无.药物警戒概述[J].中国药物警戒,2009,6(1):60-62. 被引量:4
二级引证文献2
-
1黄莉婷,陆世娟,陆朝甫.我国药物警戒体系建设的现状与发展趋势[J].药学与临床研究,2014,22(1):96-99. 被引量:16
-
2张瑞辉,叶志琼,成明建,黎婉红,陈燕平.“中药注射剂安全信息库”药物警戒模型的效果探究[J].沈阳医学院学报,2016,18(2):84-86. 被引量:3
-
1李拥军.奥美拉唑与泮托拉唑治疗消化性溃疡的随机对照研究[J].今日健康,2015,14(5):72-72.
-
2Chan AT,Ogino S,Fuchs CS,阴慧娟,李天星.阿司匹林与结直肠癌存活率的关系[J].中国处方药,2009,8(9):43-43.
-
3寇于营,徐艳霞,李晓蓉,王丽娟,阮金秀,刘克良,薛明.苯环壬酯对映体在大鼠体内的药物动力学及外消旋体的尿排泄[J].中国药理学通报,2007,23(7):959-963.
-
4翟铜广,宋广飞,库谦.麝香保心丸治疗冠心病的临床疗效评价[J].新疆中医药,2016,34(3):15-16. 被引量:6
-
5王娜,贾俐萍,张伟东,王莉,郭琼杰,刘兰祥,魏鹍.医院抗菌药物临床应用专项整治持续效果分析[J].中国医院管理,2013,33(8):53-55. 被引量:8
-
6戴景山,段思源,黄付平,王平.全国药品上市后风险管理研讨会在西安召开[J].中国医药指南,2005,3(8):11-11.
-
7张敏.时间对华蟾素注射液含量测定的影响[J].安徽中医学院学报,2005,24(5):45-45. 被引量:3
-
8曹杉,吴惠子,周淦,张伟,周宏灏.药物基因组学在传染性疾病中的研究进展[J].中国新药杂志,2011,20(13):1198-1202.
-
9杨依晗,马爱霞.效益风险评价概述[J].上海医药,2009,30(1):35-36. 被引量:5
-
10谭旭,王婷婷.17β-雌二醇对星形胶质细胞中二价金属离子转运体1表达的影响[J].中国组织工程研究,2015,19(B05):17-18.